Business
Since 2021, a growing and significant part of the revenue from our business is derived from preclinical development services, which include protocol consultation and solutions for preclinical study design and execution.
ClearPoint Neuro, Inc.: Revenue grew 17.8% to $36.97M from $31.39M. Net loss widened to $25.54M from $18.91M. Free cash flow outflow widened to $24.45M from $9.225M. Operating margin contracted 249 bps to -65.36%. ClearPoint Neuro, Inc.'s annual comparison also shows free cash flow declined despite revenue growth; capital spending grew faster than revenue; inventory grew faster than revenue; the manipulation screen is flagged and should be investigated as a warning rather than treated as proof.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 17.8% to $36.97M from $31.39MOK
- Profitability — Net loss widened to $25.54M from $18.91MWatch
- Cash flow — Free cash flow outflow widened to $24.45M from $9.225MWatch
- Margins — Operating margin contracted 249 bps to -65.36%Watch
- Accounting — Flagged statistical warning; not proofWatch
- Insiders — 0 purchases and 4 salesWatch
Where the revenue comes from
Fiscal 2025, as ClearPoint Neuro, Inc. reports it. History and quarterly detail are in the app.
- Product$23.9M
- Biologics And Drug Delivery$19.0M
- Neurosurgery Navigation And Therapy$14.8M
- Neurosurgery Navigation And Therapy Disposable Products$14.8M
- Service$13.1M
Latest filings
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-05-21
- 10-Q · Quarterly report2026-05-13
- 8-K · Company announcement2026-05-13
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ClearPoint Neuro, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.